- Home
- MERC vs DMAC Comparison
MERC vs DMAC Comparison
Compare MERC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- DMAC
- Stock Information
- Founded
- MERC 1968
- DMAC 2000
- Country
- MERC Canada
- DMAC United States
- Employees
- MERC N/A
- DMAC N/A
- Industry
- MERC Paper
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- DMAC Health Care
- Exchange
- MERC Nasdaq
- DMAC Nasdaq
- Market Cap
- MERC 271.5M
- DMAC 310.1M
- IPO Year
- MERC 1987
- DMAC N/A
- Fundamental
- Price
- MERC $3.05
- DMAC $6.87
- Analyst Decision
- MERC Hold
- DMAC Strong Buy
- Analyst Count
- MERC 3
- DMAC 3
- Target Price
- MERC $4.67
- DMAC $12.33
- AVG Volume (30 Days)
- MERC 484.3K
- DMAC 448.5K
- Earning Date
- MERC 10-30-2025
- DMAC 11-12-2025
- Dividend Yield
- MERC 9.74%
- DMAC N/A
- EPS Growth
- MERC N/A
- DMAC N/A
- EPS
- MERC N/A
- DMAC N/A
- Revenue
- MERC $1,951,044,000.00
- DMAC N/A
- Revenue This Year
- MERC N/A
- DMAC N/A
- Revenue Next Year
- MERC $13.33
- DMAC N/A
- P/E Ratio
- MERC N/A
- DMAC N/A
- Revenue Growth
- MERC N/A
- DMAC N/A
- 52 Week Low
- MERC $2.59
- DMAC $3.19
- 52 Week High
- MERC $8.28
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- MERC 42.99
- DMAC 63.84
- Support Level
- MERC $3.07
- DMAC $6.83
- Resistance Level
- MERC $3.29
- DMAC $7.41
- Average True Range (ATR)
- MERC 0.14
- DMAC 0.43
- MACD
- MERC 0.00
- DMAC 0.03
- Stochastic Oscillator
- MERC 5.71
- DMAC 73.62
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.